Implementation of Digital CBT for Insomnia in First Episode Psychosis
Launched by NHS GREATER GLASGOW AND CLYDE · Sep 17, 2021
Trial Information
Current as of May 17, 2025
Unknown status
Keywords
ClinConnect Summary
First episode psychosis (FEP) services present a unique opportunity to effect change in outcomes in those affected by experiences of psychosis. Sleep disorder, particularly insomnia, is common in those affected by psychosis, including those experiencing a first episode and are associated with increased symptomatology. Mood and worry mediate the relationship between sleep and psychosis symptomatology and research suggests that improving sleep in this population can improve mental health symptomatology and longer term outcomes. Cognitive Behavioural Therapy is effective in treating insomnia (...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Service users under the care of Esteem First Episode Psychosis Service in NHS GGC
- • Potentially affected by Insomnia Disorder (defined by Sleep Condition Indicator-02 score ≤2)
- • Who have access to a device they can use Sleepio on (a computer device with Safari or Google Chrome browser, or an iPhone device).
- Exclusion Criteria:
- • Moderate to severe learning disability
- • Acute Psychosis (recent crisis contact or hospitalisation)
- • Incapacity to provide informed consent
- • Insufficient English to access intervention
- • Organic impairment
- • No access to a device which can be used for Sleepio intervention.
About Nhs Greater Glasgow And Clyde
NHS Greater Glasgow and Clyde (NHS GG&C) is one of the largest health organizations in the UK, dedicated to delivering high-quality healthcare services to a diverse population. As a clinical trial sponsor, NHS GG&C plays a pivotal role in advancing medical research and improving patient outcomes through innovative clinical studies. The organization is committed to upholding rigorous ethical standards and regulatory compliance, ensuring that all trials are conducted with the utmost care for participant safety and scientific integrity. With a focus on collaboration, NHS GG&C partners with academic institutions, healthcare professionals, and industry stakeholders to foster an environment conducive to groundbreaking research and the development of new therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Glasgow, , United Kingdom
Glasgow, , United Kingdom
Patients applied
Trial Officials
Andrew Gumley
Principal Investigator
NHS Greater Glasgow and Clyde; University of Glasgow
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials